Abstract | OBJECTIVE: METHODS: Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT. RESULTS: From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post- mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post- mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1-2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%). CONCLUSION: The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC. ADVANCES IN KNOWLEDGE: The largest series of this association.
|
Authors | V Pernin, L Belin, P Cottu, P Bontemps, C Lemanski, B De La Lande, P Baumann, F Missohou, C Levy, K Peignaux, A Reynaud-Bougnoux, F Denis, A Gobillion, M Bollet, N A Vago, R Dendale, F Campana, A Fourquet, Y M Kirova |
Journal | The British journal of radiology
(Br J Radiol)
Vol. 88
Issue 1048
Pg. 20140800
(Apr 2015)
ISSN: 1748-880X [Electronic] England |
PMID | 25645108
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Bevacizumab
|
Topics |
- Adult
- Angiogenesis Inhibitors
(adverse effects)
- Antibodies, Monoclonal, Humanized
(adverse effects)
- Bevacizumab
- Breast Neoplasms
(drug therapy, radiotherapy, surgery)
- Chemotherapy, Adjuvant
(adverse effects)
- Female
- France
- Humans
- Lymphatic Metastasis
(radiotherapy)
- Mastectomy
- Middle Aged
- Radiotherapy, Adjuvant
(adverse effects)
- Treatment Outcome
|